Abbott Named One of the Top 10 Companies in Calvert Diversity Survey
- Details
- Category: Abbott
Abbott (NYSE: ABT) has been named one of the Top 10 companies for diversity in a new survey conducted by Calvert Group. The survey reviewed the diversity programs, policies and performance of all companies in the Standard & Poor's 100 Index (S&P 100).
Roche obtains license for EGFR lung cancer assays and will develop Tarceva companion diagnostic test
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has obtained a worldwide sublicense from Genzyme Corporation to develop a diagnostic assay for the detection of Epidermal Growth-Factor Receptor (EGFR) mutations.
Bayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies with VEGF Trap-Eye
- Details
- Category: Bayer
Bayer HealthCare and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint.
Abbott Announces Positive Results from Phase 2 Study of Low Dose Atrasentan for Treatment of Diabetic Kidney Disease
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced positive results from a Phase 2 dose-ranging study of atrasentan, a highly selective endothelin A receptor antagonist in development to help slow chronic kidney disease (CKD) progression in patients with type 2 diabetic nephropathy (diabetic kidney disease).
APPRAISE-2 Study with Investigational Compound Apixaban Discontinued
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) reported that the companies have discontinued the Phase 3 APPRAISE-2 clinical trial in patients with recent Acute Coronary Syndrome (ACS) treated with apixaban or placebo in addition to mono or dual antiplatelet therapy.
Novartis unveils long-term strategy to grow in a dynamically changing healthcare environment
- Details
- Category: Novartis
Novartis presented a strategic overview of the company's diversified healthcare portfolio which creates the potential for future sustainable growth. The company's focused healthcare portfolio across key growth segments in healthcare provides Novartis a leading position in the respective market segments.
Genzyme Announces Agreement to Sell Diagnostics Business
- Details
- Category: Genzyme
Genzyme Corporation (Nasdaq: GENZ) announced that it has entered into an asset purchase agreement under which Sekisui Chemical Co., Ltd. will acquire Genzyme's Diagnostic products business for $265 million in cash.
More Pharma News ...
- Pfizer Launches Global Centers for Therapeutic Innovation
- Roche announces implementation plans for its Operational Excellence Program
- Boehringer Ingelheim steps up to the challenge in support of World Diabetes Day
- Adding INSPRA® (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity
- Rivaroxaban Significantly Reduces Risk of Stroke with Comparable Safety versus Warfarin
- Diabetes awareness survey reveals alarming figures across the Middle East and Northern Africa regions
- Collaboration of Boehringer Ingelheim and VTU Technology